Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial-Reference-Cited by-同舟云学术

Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial

Published:2015-05 Issue:5 Volume:169 Page:622-630.e6
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

O’Donoghue Michelle L.,Glaser Ruchira,Aylward Philip E.,Cavender Matthew A.,Crisp Adam,Fox Keith A.A.,Laws Ian,Lopez-Sendon Jose L.,Steg P. Gabriel,Theroux Pierre,Sabatine Marc S.,Morrow David A.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference24 articles.

1. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study);Fox;Eur Heart J,2010

2. Inflammation in atherosclerosis;Libby;Nature,2002

3. The p38 mitogen-activated protein kinase pathway—a potential target for intervention in infarction, hypertrophy, and heart failure;Marber;J Mol Cell Cardiol,2011

4. New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease;Denise Martin;Circulation,2012

5. p38 mitogen-activated protein kinase: a future target for heart failure therapy?;Kerkela;J Am Coll Cardiol,2006

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atherosclerosis and inflammation: therapeutic targets and ways of correction;The Clinician;2024-06-23

2. Novel small-molecule compound VCP979 attenuates renal fibrosis in male rats with unilateral ureteral obstruction;Experimental Biology and Medicine;2023-01-30

3. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention;Signal Transduction and Targeted Therapy;2022-04-22

4. Protein kinases in cardiovascular diseases;Chinese Medical Journal;2022-02-02

5. Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE–TIMI 60 trial;American Heart Journal;2022-01